Vanguard Group Inc Aadi Bioscience, Inc. Transaction History

Vanguard Group Inc

$4.96 Trillion
Q1 2024

A detailed history of Vanguard Group Inc transactions in Aadi Bioscience, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 856,836 shares of AADI stock, worth $1.64 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

856,836

Previous 859,697 0.33%

Holding current value

$1.64 Million

Previous $1.74 Million 15.44%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$1.59 - $2.44 $4,548 - $6,980	-2,861 Reduced 0.33%	856,836 $2 Million
Q4 2023 Feb 14, 2024	BUY	$1.97 - $5.41 $173,976 - $477,773	88,313 Added 11.45%	859,697 $1.74 Million
Q3 2023 Nov 14, 2023	BUY	$4.84 - $7.13 $45,883 - $67,592	9,480 Added 1.24%	771,384 $3.73 Million
Q2 2023 Aug 14, 2023	SELL	$6.84 - $8.56 $67,182 - $84,076	-9,822 Reduced 1.27%	761,904 $5.21 Million
Q1 2023 May 15, 2023	BUY	$6.85 - $13.0 $225,947 - $428,805	32,985 Added 4.47%	771,726 $5.59 Million

Q4 2022 Feb 10, 2023	SELL	$11.99 - $14.5 $29,111 - $35,206	-2,428 Reduced 0.33%	738,741 $9.48 Million
Q3 2022 Nov 14, 2022	SELL	$12.03 - $14.22 $1.11 Million - $1.32 Million	-92,658 Reduced 11.11%	741,169 $10.5 Million
Q2 2022 Aug 12, 2022	BUY	$11.57 - $17.92 $850,904 - $1.32 Million	73,544 Added 9.67%	833,827 $10.3 Million
Q1 2022 May 13, 2022	SELL	$16.65 - $24.97 $19,813 - $29,714	-1,190 Reduced 0.16%	760,283 $12.9 Million
Q4 2021 Feb 14, 2022	BUY	$19.32 - $29.02 $12.4 Million - $18.7 Million	643,196 Added 543.8%	761,473 $18.4 Million
Q3 2021 Nov 12, 2021	BUY	$25.52 - $41.85 $3.02 Million - $4.95 Million	118,277 New	118,277 $3.47 Million

Others Institutions Holding AADI

# of Institutions

Shares Held

13.7M

Call Options Held

4.9K

Put Options Held

700

View Full List

About Aadi Bioscience, Inc.

Ticker AADI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,016,800
Market Cap $40.1M
Description
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...

More about AADI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Aadi Bioscience, Inc. Transaction History